Avidity-controlled delivery of angiogenic peptides from injectable molecular-recognition hydrogels

Tissue Engineering - Part A

Volumn 20, Issue 15-16, 2014, Pages 2102-2114

  Mulyasasmita, Widya ^a   Cai, Lei ^a   Hori, Yuki ^a   Heilshorn, Sarah C ^a  

^a Stanford University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOACTIVITY; BIOMIMETICS; ENCAPSULATION; ENDOTHELIAL CELLS; HYDROGELS; MIXING; SIGNAL TRANSDUCTION;

HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; INTESTINAL PERMEABILITIES; PROLINE-RICH SEQUENCES; REVERSIBLE INTERACTIONS; SPATIOTEMPORAL CONTROL; THERAPEUTIC ANGIOGENESIS; THREE-DIMENSIONAL MODEL; VASCULAR ENDOTHELIAL GROWTH FACTOR;

PEPTIDES;

COLLAGEN; FIBRONECTIN; PEPTIDOMIMETIC AGENT; PROLINE; QK PEPTIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ANGIOGENIC PROTEIN; DELAYED RELEASE FORMULATION; HYDROGEL; PROTEIN BINDING;

ANGIOGENESIS; ARTICLE; BINDING AFFINITY; CELL GROWTH; CELL MIGRATION; CELL STRUCTURE; CONJUGATE; CONJUGATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIFFUSION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; ENCAPSULATION; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; HUMAN; HUMAN CELL; HYDROGEL; MIXING INDUCED TWO COMPONENT HYDROGEL; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; MOLECULAR WEIGHT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN IMMOBILIZATION; SIGNAL TRANSDUCTION; SPHEROID CELL; SUSTAINED DRUG RELEASE; UMBILICAL VEIN ENDOTHELIAL CELL; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; INJECTION; METABOLISM;

ANGIOGENIC PROTEINS; CELL MOVEMENT; CELL PROLIFERATION; DELAYED-ACTION PREPARATIONS; DIFFUSION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROGELS; INJECTIONS; NEOVASCULARIZATION, PHYSIOLOGIC; PHENOTYPE; PROTEIN BINDING; SIGNAL TRANSDUCTION;

EID: 84906535822     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2013.0357     Document Type: Article

References (61)

1. Vlieghe, P., Lisowski, V., Martinez, J., and Khrestchatisky, M. Synthetic therapeutic peptides: Science and market. Drug Discov Today 15, 40, 2010.
2. Craik, D.J., Fairlie, D.P., Liras, S., and Price, D. The future of peptide-based drugs. Chem Biol Drug Des 81, 136, 2013.
3. Vanhee, P., et al. Computational design of peptide ligands. Trends Biotechnol 29, 231, 2011.
4. Otvos, L., Jr. Peptide-based drug design: Here and now. Methods Mol Biol 494, 1, 2008.
5. Kumar, A., Voet, A., and Zhang, K.Y. Fragment based drug design: From experimental to computational approaches. Curr Med Chem 19, 5128, 2012.
6. D'Andrea, L.D., et al. Targeting angiogenesis: Structural characterization and biological properties of a de novo engineered VEGF mimicking peptide. Proc Natl Acad Sci USA 102, 14215, 2005.
7. Lin, X., Takahashi, K., Liu, Y., Derrien, A., and Zamora, P.O. A synthetic, bioactive PDGF mimetic with binding to both alpha-PDGF and beta-PDGF receptors. Growth Factors 25, 87, 2007.
8. LeSauteur, L., Wei, L., Gibbs, B.F., and Saragovi, H.U. Small peptide mimics of nerve growth factor bind TrkA receptors and affect biological responses. J Biol Chem 270, 6564, 1995.
9. Xiao, J., et al. A small peptide mimetic of brain-derived neurotrophic factor promotes peripheral myelination. J Neurochem 125, 386, 2013.
10. Nakamura, T., et al. Peptide mimics of epidermal growth factor (EGF) with antagonistic activity. J Biotechnol 116, 211, 2005.
11. Tang, L., Persky, A.M., Hochhaus, G., and Meibohm, B. Pharmacokinetic aspects of biotechnology products. J Pharm Sci 93, 2184, 2004.
12. Lipinski, C.A. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44, 235, 2000.
13. Harris, J.M., and Chess, R.B. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2, 214, 2003.
14. Szlachcic, A., Zakrzewska, M., and Otlewski, J. Longer action means better drug: Tuning up protein therapeutics. Biotechnol Adv 29, 436, 2011.
15. Censi, R., Di Martino, P., Vermonden, T., and Hennink, W.E. Hydrogels for protein delivery in tissue engineering. J Control Release 161, 680, 2012.
16. Katz, J.S., and Burdick, J.A. Hydrogel mediated delivery of trophic factors for neural repair. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1, 128, 2009.
17. Gonen-Wadmany, M., Goldshmid, R., and Seliktar, D. Biological and mechanical implications of PEGylating proteins into hydrogel biomaterials. Biomaterials 32, 6025, 2011.
18. Veronese, F.M., and Mero, A. The impact of PEGylation on biological therapies. BioDrugs 22, 315, 2008.
19. Lin, C.C., Boyer, P.D., Aimetti, A.A., and Anseth, K.S. Regulating MCP-1 diffusion in affinity hydrogels for enhancing immuno-isolation. J Control Release 142, 384, 2010.
20. Wylie, R.G., et al. Spatially controlled simultaneous patterning of multiple growth factors in three-dimensional hydrogels. Nat Mater 10, 799, 2011.
21. Nie, T., Akins, R.E., Jr., and Kiick, K.L. Production of heparin-containing hydrogels for modulating cell responses. Acta Biomater 5, 865, 2009.
22. Sakiyama-Elbert, S.E., and Hubbell, J.A. Controlled release of nerve growth factor from a heparin-containing fibrinbased cell ingrowth matrix. J Control Release 69, 149, 2000.
23. Sakiyama-Elbert, S.E., and Hubbell, J.A. Development of fibrin derivatives for controlled release of heparin-binding growth factors. J Control Release 65, 389, 2000.
24. Wood, M.D., and Sakiyama-Elbert, S.E. Release rate controls biological activity of nerve growth factor released from fibrin matrices containing affinity-based delivery systems. J Biomed Mater Res A 84, 300, 2008.
25. Wong Po Foo, C.T., Lee, J.S., Mulyasasmita, W., Parisi-Amon, A., and Heilshorn, S.C. Two-component proteinengineered physical hydrogels for cell encapsulation. Proc Natl Acad Sci USA 106, 22067, 2009.
26. Mulyasasmita, W., Lee, J.S., and Heilshorn, S.C. Molecular-level engineering of protein physical hydrogels for predictive sol-gel phase behavior. Biomacromolecules 12, 3406, 2011.
27. Parisi-Amon, A., Mulyasasmita, W., Chung, C., and Heilshorn, S.C. Protein-engineered injectable hydrogel to improve retention of transplanted adipose-derived stem cells. Adv Healthc Mater 2, 428, 2013.
28. Finetti, F., et al. Functional and pharmacological characterization of a VEGF mimetic peptide on reparative angiogenesis. Biochem Pharmacol 84, 303, 2012.
29. Lee, J.S., Wagoner Johnson, A.J., and Murphy, W.L. A modular, hydroxyapatite-binding version of vascular endothelial growth factor. Adv Mater 22, 5494, 2010.
30. Chan, T.R., Stahl, P.J., and Yu, S.M. Matrix-bound VEGF mimetic peptides: Design and endothelial-cell activation in collagen scaffolds. Adv Funct Mater 21, 4252, 2011.
31. Koepsel, J.T., Nguyen, E.H., and Murphy, W.L. Differential effects of a soluble or immobilized VEGFR-binding peptide. Integr Biol 4, 914, 2012.
32. Jonsson, P., Jonsson, M.P., Tegenfeldt, J.O., and Hook, F. A method improving the accuracy of fluorescence recovery after photobleaching analysis. Biophys J 95, 5334, 2008.
33. Guo, Q., Knight, P.T., and Mather, P.T. Tailored drug release from biodegradable stent coatings based on hybrid polyurethanes. J Control Release 137, 224, 2009.
34. Davis, J. Animal Models: A Practical Guide to Creating and Using Culture-Based Biomimetic Alternatives. Hoboken, NJ: Wiley-Blackwell, 2012.
35. Krishnamurthy, V.M., Estroff, L.A., and Whitesides, G.M. Multivalency in Ligand Design, in Fragment-based Approaches in Drug Discovery. Weinheim, FRG: Wiley-VCH Verlag GmbH & Co. KGaA, 2006.
36. Brandl, F., et al. Hydrogel-based drug delivery systems: Comparison of drug diffusivity and release kinetics. J Control Release 142, 221, 2010.
37. Hirota, N., Kumaki, Y., Narita, T., Gong, J.P., and Osada, Y. Effect of charge on protein diffusion in hydrogels. J Phys Chem B 104, 9898, 2000.
38. de Gennes, P.G. Scaling Concepts in Polymer Physics. Ithaca, NY: Cornell University Press, 1979.
39. Colby, R.H. Dynamics in blends of long polymers with unentangled short chains. J Phys II 7, 93, 1997.
40. Bochicchio, B., and Tamburro, A.M. Polyproline II structure in proteins: Identification by chiroptical spectroscopies, stability, and functions. Chirality 14, 782, 2002.
41. Olsson, A.K., Dimberg, A., Kreuger, J., and Claesson-Welsh, L. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 7, 359, 2006.
42. Zhang, Y., Furumura, M., and Morita, E. Distinct signaling pathways confer different vascular responses to VEGF 121 and VEGF 165. Growth Factors 26, 125, 2008.
43. Munoz-Chapuli, R., Quesada, A.R., and Angel Medina, M. Angiogenesis and signal transduction in endothelial cells. Cell Mol Life Sci 61, 2224, 2004.
44. Deroanne, C.F., Lapiere, C.M., and Nusgens, B.V. In vitro tubulogenesis of endothelial cells by relaxation of the coupling extracellular matrix-cytoskeleton. Cardiovasc Res 49, 647, 2001.
45. Swendeman, S., et al. VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling. Circ Res 103, 916, 2008.
46. Shamloo, A., and Heilshorn, S.C. Matrix density mediates polarization and lumen formation of endothelial sprouts in VEGF gradients. Lab Chip 10, 3061, 2010.
47. Lin, J.H., and Lu, A.Y. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 49, 403, 1997.
48. Dalby, P.A., Hoess, R.H., and DeGrado, W.F. Evolution of binding affinity in a WW domain probed by phage display. Protein Sci 9, 2366, 2000.
49. Yaffe, M.B., and Smerdon, S.J. The use of in vitro peptidelibrary screens in the analysis of phosphoserine/threoninebinding domain structure and function. Annu Rev Biophys Biomol Struct 33, 225, 2004.
50. Kortt, A.A., Dolezal, O., Power, B.E., and Hudson, P.J. Dimeric and trimeric antibodies: High avidity scFvs for cancer targeting. Biomol Eng 18, 95, 2001.
51. Lei, Y., Haider, H., Shujia, J., and Sim, E.S. Therapeutic angiogenesis. Devising new strategies based on past experiences. Basic Res Cardiol 99, 121, 2004.
52. Silva, E.A., and Mooney, D.J. Effects of VEGF temporal and spatial presentation on angiogenesis. Biomaterials 31, 1235, 2010.
53. Eppler, S.M., et al. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther 72, 20, 2002.
54. Dranitsaris, G., Amir, E., and Dorward, K. Biosimilars of biological drug therapies: Regulatory, clinical and commercial considerations. Drugs 71, 1527, 2011.
55. Yancopoulos, G.D., et al. Vascular-specific growth factors and blood vessel formation. Nature 407, 242, 2000.
56. Richardson, T.P., Peters, M.C., Ennett, A.B., and Mooney, D.J. Polymeric system for dual growth factor delivery. Nat Biotechnol 19, 1029, 2001.
57. Chen, R.R., Silva, E.A., Yuen, W.W., and Mooney, D.J. Spatio-Temporal VEGF and PDGF delivery patterns blood vessel formation and maturation. Pharm Res 24, 258, 2007.
58. Freeman, I., and Cohen, S. The influence of the sequential delivery of angiogenic factors from affinity-binding alginate scaffolds on vascularization. Biomaterials 30, 2122, 2009.
59. Lin, C.C., and Metters, A.T. Bifunctional monolithic affinity hydrogels for dual-protein delivery. Biomacromolecules 9, 789, 2008.
60. Kim, S., et al. Sequential delivery of BMP-2 and IGF-1 using a chitosan gel with gelatin microspheres enhances early osteoblastic differentiation. Acta Biomater 8, 1768, 2012.
61. Xu, W., Atala, A., Yoo, J.J., and Lee, S.J. Controllable dual protein delivery through electrospun fibrous scaffolds with different hydrophilicities. Biomed Mater 8, 014104, 2013.